Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial dataGESSER, Richard M; MCCARROLL, Kathleen; TEPPLER, Hedy et al.Journal of antimicrobial chemotherapy (Print). 2003, Vol 51, Num 5, pp 1253-1260, issn 0305-7453, 8 p.Article

Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infectionsDINUBILE, Mark J; CHOW, Joseph W; SATISHCHANDRAN, Vilas et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 8, pp 3217-3221, issn 0066-4804, 5 p.Article

Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adultsYELLIN, Albert E; HASSETT, James M; FERNANDEZ, Alvaro et al.International journal of antimicrobial agents. 2002, Vol 20, Num 3, pp 165-173, issn 0924-8579, 9 p.Article

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment- Experienced Patients with Drug- Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III TrialsSTEIGBIGEL, Roy T; COOPER, David A; YENI, Patrick et al.Clinical infectious diseases. 2010, Vol 50, Num 4, pp 605-612, issn 1058-4838, 8 p.Article

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 InfectionMARKOWITZ, Martin; NGUYEN, Bach-Yen; CAMPBELL, Havilland et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, Num 3, pp 350-356, issn 1525-4135, 7 p.Article

Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 YearsNACHMAN, Sharon; NAN ZHENG; FRENKEL, Lisa M et al.Clinical infectious diseases. 2014, Vol 58, Num 3, pp 413-422, issn 1058-4838, 10 p.Article

Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionSTEIGBIGEL, Roy T; COOPER, David A; KATLAMA, Christine et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 339-354, issn 0028-4793, 16 p.Article

Safety and tolerability of ertapenemTEPPLER, Hedy; GESSER, Richard M; FRIEDLAND, Ian R et al.Journal of antimicrobial chemotherapy (Print). 2004, Vol 53, pp ii75-ii81, issn 0305-7453, SUP2Article

Lack of a Significant Drug Interaction between Raltegravir and TenofovirWENNING, Larissa A; FRIEDMAN, Evan J; STONE, Julie A et al.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 9, pp 3253-3258, issn 0066-4804, 6 p.Article

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionCOOPER, David A; STEIGBIGEL, Roy T; SCHECHTER, Mauro et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 355-365, issn 0028-4793, 11 p.Article

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropeniaWALSH, Thomas J; TEPPLER, Hedy; DEPAUW, Ben E et al.The New England journal of medicine. 2004, Vol 351, Num 14, pp 1391-1402, issn 0028-4793, 12 p.Article

Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004)GOTUZZO, Eduardo; MARKOWITZ, Martin; TEPPLER, Hedy et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 61, Num 1, pp 73-77, issn 1525-4135, 5 p.Article

Effects of Omeprazole on Plasma Levels of RaltegravirIWAMOTO, Arian; WENNING, Larissa A; AZROLAN, Neal et al.Clinical infectious diseases. 2009, Vol 48, Num 4, pp 489-492, issn 1058-4838, 4 p.Article

In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide : the 2003 study for Monitoring Antimicrobial Resistance Trends (SMART)PATERSON, David L; ROSSI, Flavia; CHOW, Joseph W et al.Journal of antimicrobial chemotherapy (Print). 2005, Vol 55, Num 6, pp 965-973, issn 0305-7453, 9 p.Article

Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4⁺ T-cell decline or improve other indices of immune function: Results of a randomized controlled Clinical trial (ACTG 248)VOGLER, Mary A; TEPPLER, Hedy; FRANK, Ian et al.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 36, Num 1, pp 576-587, issn 1525-4135, 12 p.Article

Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: Results of a double-blind, randomized comparative phase III trialSOLOMKIN, Joseph S; YELLIN, Albert E; SATISHCHANDRAN, Vilas et al.Annals of surgery. 2003, Vol 237, Num 2, pp 235-245, issn 0003-4932, 11 p.Article

Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS clinical trials group 267WOHL, David A; AWEEKA, Francesca T; THOMAS, Steven et al.The Journal of infectious diseases. 2002, Vol 185, Num 9, pp 1359-1363, issn 0022-1899Article